Thrombophilia Due to Thrombin Defect disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

THPH1 MCID: THR092 MIFTS: 76	Thrombophilia Due to Thrombin Defect (THPH1) Categories: Blood diseases, Bone diseases, Cardiovascular diseases, Genetic diseases, Immune diseases, Rare diseases, Respiratory diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Thrombophilia Due to Thrombin Defect

MalaCards integrated aliases for Thrombophilia Due to Thrombin Defect:

Name: Thrombophilia Due to Thrombin Defect ⁵⁷ ¹¹ ⁷³ ²⁸ ⁵ ¹⁴

Venous Thromboembolism ⁵⁷ ⁷³ ⁵ ¹⁶ ⁷¹ ³³

Venous Thrombosis ⁵⁷ ⁷³ ²⁸ ⁵³ ⁷¹ ⁷⁵

Thrombophilia Due to Factor 2 Defect ⁵⁷ ¹¹ ¹⁹ ⁷³

Thromboembolism ⁵⁷ ⁵³ ⁵ ⁷¹

Venous Thromboembolism, Susceptibility to ⁵⁷ ²⁸ ⁵

Thromboembolism, Susceptibility to ⁵⁷ ²⁸ ¹²

Thph1 ⁵⁷ ¹¹ ⁷³

Venous Thrombosis, Protection Against ⁵⁷ ⁵

Venous Thrombosis, Susceptibility to ²⁸ ⁵

Prothrombin-Related Thrombophilia ¹¹ ¹⁹

Hyperprothrombinemia ¹⁹ ⁷¹

Thrombophilia 1 Due to Thrombin Defect ⁵⁷

Prothrombin 20210g>a Thrombophilia ¹⁹

Prothrombin G20210a Thrombophilia ¹⁹

Factor Ii-Related Thrombophilia ¹⁹

Prothrombin Thrombophilia ¹⁹

F2-Related Thrombophilia ¹⁹

Characteristics:

Inheritance:

Autosomal dominant ⁵⁷

OMIM®:

⁵⁷ (Updated 08-Dec-2022)

Miscellaneous:
onset in childhood

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Cardiovascular diseases Blood diseases Respiratory diseases Immune diseases Bone diseases

See all MalaCards categories (disease lists)

ICD11: ³³

Diseases of the circulatory system

Diseases of veins

Venous thromboembolism

External Ids:

Disease Ontology ¹¹ DOID:0111907

OMIM® ⁵⁷ 188050

OMIM Phenotypic Series ⁵⁷ PS188050

MeSH ⁴³ D019851

MedGen ⁴⁰ C0398623 C1861172 C3160733

SNOMED-CT via HPO ⁶⁹ 128053003 13713005 371039008 more

EFO ¹⁶ EFO_0004286

ICD11 ³³ 1197943614

UMLS ⁷¹ C0040038 C0042487 C1861172 more

Sources

Summaries for Thrombophilia Due to Thrombin Defect

GARD: ¹⁹ Prothrombin-related thrombophilia affects the way the blood clots. Individuals who have a thrombophilia have an increased risk to form abnormal blood clots in blood vessels. Symptoms of Prothrombin-related thrombophilia include a higher than average risk to develop blood clots in the deep veins of the legs (deep venous thrombosis) and blood clots in the lungs (pulmonary embolism). Many people with Prothrombin-related thrombophilia never develop abnormal blood clots. This condition is caused by a particular genetic variant (written G20210A or 20210G>A) in the F2 gene and is inherited in an autosomal dominant pattern. Prothrombin-related thrombophilia is diagnosed based on the symptoms, physical exam, blood tests, and imaging studies. The diagnosis may be confirmed by the results of genetic testing.

MalaCards based summary: Thrombophilia Due to Thrombin Defect, also known as venous thromboembolism, is related to homocysteinemia and cerebral sinovenous thrombosis. An important gene associated with Thrombophilia Due to Thrombin Defect is F13A1 (Coagulation Factor XIII A Chain), and among its related pathways/superpathways are Collagen chain trimerization and Response to elevated platelet cytosolic Ca2+. The drugs Dronedarone and Atorvastatin have been mentioned in the context of this disorder. Affiliated tissues include lung, spinal cord and liver, and related phenotypes are pulmonary embolism and deep venous thrombosis

OMIM®: ⁵⁷ Thrombophilia is a multifactorial disorder of inappropriate clot formation resulting from an interaction of genetic, acquired, and circumstantial predisposing factors. Venous thromboembolism most commonly manifests as deep vein thrombosis, which may progress to pulmonary embolism if the clot dislodges and travels to the lung. Other manifestations include thromboses of the cerebral or visceral veins and recurrent pregnancy loss (summary by Seligsohn and Lubetsky, 2001 and Varga and Kujovich, 2012). (188050) (Updated 08-Dec-2022)

UniProtKB/Swiss-Prot: ⁷³ A multifactorial disorder of hemostasis characterized by abnormal platelet aggregation in response to various agents and recurrent thrombi formation.

Disease Ontology: ¹¹ A thrombophilia characterized by recurrent thrombophilia that has material basis in heterozygous mutation in F2 on chromosome 11p11.2.

Wikipedia: ⁷⁵ Venous thrombosis is blockage of a vein caused by a thrombus (blood clot). A common form of venous... more...

Sources

Related Diseases for Thrombophilia Due to Thrombin Defect

Diseases in the Thrombophilia family:

Thrombophilia Due to Thrombin Defect	Thrombophilia Due to Activated Protein C Resistance
Thrombophilia, Familial, Due to Decreased Release of Tissue Plasminogen Activator	Thrombophilia Due to Thrombomodulin Defect
Thrombophilia Due to Decreased Release of Plat	Rare Hereditary Thrombophilia

Diseases related to Thrombophilia Due to Thrombin Defect via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1733)

#	Related Disease	Score	Top Affiliating Genes
1	homocysteinemia	32.2	MTHFR F5 F2
2	cerebral sinovenous thrombosis	31.5	F5 F2
3	antithrombin iii deficiency	31.4	SERPINC1 PF4 MTHFR FGA F5 F3
4	vitamin k deficiency bleeding	31.4	SERPINC1 F8 F3 F2
5	intracranial hypertension	31.3	SERPINC1 F5 F3 F2 APOH
6	polycythemia	31.3	F5 F3 F2
7	papilledema	31.2	SERPINC1 F3 F2 APOH
8	heparin-induced thrombocytopenia	31.2	PF4 F3 F2
9	protein c deficiency	31.1	THBD SERPINE1 SERPINC1 PROCR PROC MTHFR
10	hyperhomocysteinemia	31.1	VWF THBD SERPINE1 SERPINC1 PLAT MTHFR
11	intracranial hypotension	31.1	SERPINC1 MTHFR F3 F2
12	portal vein thrombosis	31.0	VWF THBD SERPINC1 PF4 MTHFR F8
13	post-thrombotic syndrome	31.0	VWF THBD SERPINE1 SERPINC1 PLAT F8
14	hemoglobinuria	31.0	THBD SERPINC1 F2
15	hemophilia	31.0	VWF F8 F2 F10
16	venous insufficiency	30.9	VWF SERPINE1 PLAT MTHFR F5 F2
17	severe covid-19	30.9	VWF F3 F2
18	lateral sinus thrombosis	30.9	SERPINC1 MTHFR F2
19	factor viii deficiency	30.9	VWF SERPINC1 F8 F5 F3 F2
20	protein s deficiency	30.9	THBD SERPINE1 SERPINC1 PROC MTHFR FGA
21	chronic venous insufficiency	30.9	VWF SERPINE1 SERPINC1 F3 F2
22	mastoiditis	30.9	SERPINC1 MTHFR F3 F2
23	thoracic outlet syndrome	30.9	SERPINC1 PLAT F2 APOH
24	cerebrovascular disease	30.9	PLAT MTHFR F5 F2 F13A1 APOH
25	compartment syndrome	30.8	SERPINC1 F8 F3 F2
26	esophageal varix	30.8	SERPINC1 F3 F2
27	varicose veins	30.8	VWF THBD SERPINC1 PLAT MTHFR F5
28	thrombophilia due to activated protein c resistance	30.8	VWF THBD SERPINE1 SERPINC1 MTHFR F8
29	sickle cell anemia	30.7	VWF SERPINC1 F3 F2
30	lemierre's syndrome	30.7	SERPINC1 F3 F2
31	thrombocytopenia due to platelet alloimmunization	30.7	VWF PF4 F3
32	abducens palsy	30.7	SERPINC1 F2
33	limb ischemia	30.6	VWF SERPINC1 F3
34	behcet syndrome	30.6	VWF THBD SERPINC1 MTHFR F5 F3
35	arteriovenous malformation	30.6	VWF PLAT F3 F2
36	splenic infarction	30.6	SERPINC1 F3 F2 APOH
37	homocystinuria	30.6	THBD SERPINC1 MTHFR F8 F5
38	factor xii deficiency	30.6	VWF SERPINC1 F5 F3 F2 APOH
39	budd-chiari syndrome	30.6	VWF SERPINC1 MTHFR F5 F3 F2
40	thrombocytopenic purpura, autoimmune	30.6	PF4 F8 F3 F2
41	pregnancy loss, recurrent 1	30.6	MTHFR F5 APOH
42	cardiovascular system disease	30.5	VWF THBD SERPINE1 SERPINC1 PLAT PF4
43	sagittal sinus thrombosis	30.5	SERPINC1 PF4 MTHFR F5 F3 F2
44	cavernous sinus thrombosis	30.5	SERPINC1 PF4 F3 F2
45	hemophilia a	30.5	VWF F8 F5 F3 F2 F10
46	plasminogen deficiency, type i	30.5	SERPINE1 SERPINC1 PLAT
47	thrombocytosis	30.5	VWF SERPINC1 PF4 FGA F3 F2
48	ischemic colitis	30.5	SERPINC1 F3 F2
49	hypersplenism	30.5	SERPINC1 F3 F2
50	leech infestation	30.5	F3 F2

Comorbidity relations with Thrombophilia Due to Thrombin Defect via Phenotypic Disease Network (PDN): (show all 13)

Active Peptic Ulcer Disease	Acute Cystitis
Decubitus Ulcer	Deficiency Anemia
Familial Atrial Fibrillation	Femoral Vein Thrombophlebitis
Heart Disease	Hypertension, Essential
Hypothyroidism	Osteoporosis
Peripheral Vascular Disease	Protein-Energy Malnutrition
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Thrombophilia Due to Thrombin Defect:

Sources

Symptoms & Phenotypes for Thrombophilia Due to Thrombin Defect

Human phenotypes related to Thrombophilia Due to Thrombin Defect:

³⁰

#	Description	HPO Source Accession
1	pulmonary embolism ³⁰	HP:0002204
2	deep venous thrombosis ³⁰	HP:0002625
3	thromboembolism ³⁰	HP:0001907
4	cerebral venous thrombosis ³⁰	HP:0005305
5	recurrent thrombophlebitis ³⁰	HP:0004419

Symptoms via clinical synopsis from OMIM®:

⁵⁷ (Updated 08-Dec-2022)

Respiratory Lung:
pulmonary embolism

Neurologic Central Nervous System:
cerebral thrombosis

Cardiovascular Vascular:
deep vein thrombosis
thrombosis, recurrent

Clinical features from OMIM®:

188050 (Updated 08-Dec-2022)

GenomeRNAi Phenotypes related to Thrombophilia Due to Thrombin Defect according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	no effect	GR00402-S-1	10.2	APOH F10 F13A1 F13B F2 F3
2	no effect	GR00402-S-2	10.2	APOH F10 F13A1 F13B F2 F3

MGI Mouse Phenotypes related to Thrombophilia Due to Thrombin Defect:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.35	APOH F10 F13A1 F13B F2 F3
2	nervous system	MP:0003631	10.17	F2 F3 F5 FGA MTHFR PLAT
3	cardiovascular system	MP:0005385	10.17	F10 F13A1 F2 F3 F5 FGA
4	immune system	MP:0005387	10.03	F2 F3 F8 FGA HABP2 PLAT
5	liver/biliary system	MP:0005370	10.01	F5 FGA HABP2 MTHFR PROC SERPINC1
6	hematopoietic system	MP:0005397	9.97	F13A1 F2 F3 F8 FGA PF4
7	mortality/aging	MP:0010768	9.91	APOH F10 F13A1 F2 F3 F5
8	integument	MP:0010771	9.32	F13A1 F2 F3 F5 FGA MTHFR

Sources

Drugs & Therapeutics for Thrombophilia Due to Thrombin Defect

Drugs for Thrombophilia Due to Thrombin Defect (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 320)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Dronedarone

Approved

Phase 4

141626-36-0

208898

Atorvastatin

Approved

Phase 4

134523-00-5

60823

Plasminogen

Approved

Phase 4

9001-91-6

Norethisterone

Approved

Phase 4

68-22-4

199472 6230

Dydrogesterone

Approved, Investigational, Withdrawn

Phase 4

152-62-5

9051

Nadroparin

Approved, Investigational

Phase 4

Fluindione

Approved, Investigational

Phase 4

957-56-2

Rabeprazole

Approved, Investigational

Phase 4

117976-89-3, 117976-90-6

5029

Miconazole

Approved, Investigational, Vet_approved

Phase 4

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 4

23593-75-1

2812

Amoxicillin

Approved, Vet_approved

Phase 4

26787-78-0

33613

Clavulanic acid

Approved, Vet_approved

Phase 4

58001-44-8

5280980

Acetaminophen

Approved

Phase 4

103-90-2

1983

Phenindione

Approved, Investigational

Phase 4

83-12-5

4760

Verapamil

Approved

Phase 4

152-11-4, 52-53-9

2520

Streptokinase

Approved, Investigational

Phase 4

9002-01-1

Salicylic acid

Approved, Investigational, Vet_approved

Phase 4

69-72-7

338

Phylloquinone

Approved, Investigational

Phase 4

84-80-0

5284607

Dipyridamole

Approved

Phase 4

58-32-2

3108

Infliximab

Approved

Phase 4

170277-31-3

Adalimumab

Approved, Experimental

Phase 4

331731-18-1

Golimumab

Approved

Phase 4

476181-74-5

Tofacitinib

Approved, Investigational

Phase 4

477600-75-2

9926791

Apixaban

Approved

Phase 4

503612-47-3

10182969

Fondaparinux

Approved, Investigational

Phase 4

114870-03-0, 104993-28-4

5282448 636380

Phenprocoumon

Approved, Investigational

Phase 4

435-97-2

54680692 9908

Ranibizumab

Approved

Phase 4

347396-82-1

Menadione

Approved, Nutraceutical

Phase 4

58-27-5

4055

Vitamin A

Approved, Nutraceutical, Vet_approved

Phase 4

22737-96-8, 68-26-8

5280382 445354

Coumarin

Experimental

Phase 4

91-64-5

323

Menaquinone

Investigational

Phase 4

1182-68-9

Norethindrone Acetate

Phase 4

541197

Calcium, Dietary

Phase 4

Rosuvastatin Calcium

Phase 4

147098-20-2

Hormones

Phase 4

Hypolipidemic Agents

Phase 4

Anticholesteremic Agents

Phase 4

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Phase 4

Lipid Regulating Agents

Phase 4

Tin Fluorides

Phase 4

Anti-Ulcer Agents

Phase 4

Antacids

Phase 4

Proton Pump Inhibitors

Phase 4

Anti-Infective Agents

Phase 4

Antifungal Agents

Phase 4

Purinergic P2Y Receptor Antagonists

Phase 4

Anti-Bacterial Agents

Phase 4

Vasoconstrictor Agents

Phase 4

Antidotes

Phase 4

Antibodies, Antiphospholipid

Phase 4

Interventional clinical trials:

(show top 50) (show all 1329)

#	Name	Status	NCT ID	Phase	Drugs
1	A Prospective Study in Chinese Patients With Lower Extremity Ankle Fracture of Oral Anticoagulants to Prevent Venous Thromboembolism (VTE)	Unknown status	NCT04128254	Phase 4	Apixaban Oral Tablet
2	Patient Adherence to Venous Thromboembolism Prophylaxis in Orthopaedic Trauma Patients: A Randomized, Controlled Trial Comparing Subcutaneous Enoxaparin & Oral Rivaroxaban	Unknown status	NCT04169269	Phase 4	Enoxaparin 40 milligram/0.4 milliliter Injectable Syringe 0.4 milliliters;Rivaroxaban 10 milligram Oral Tablet
3	Weight Based Enoxaparin for Venous Thromboembolism Prophylaxis in Trauma Patients	Unknown status	NCT01916707	Phase 4	Dosing of enoxaparin for VTE prophylaxis
4	A Phase IV Study on Impact of Edoxaban Treatment in Italian Cancer Patients With Venous Thromboembolism (EDOI Cancer Study) During Antineoplastic Therapy	Unknown status	NCT04072068	Phase 4	Edoxaban
5	A Double-blind Randomized Trial to Compare the Efficacy of Intermittent Pneumatic Compression (IPC) With and Without Early Anticoagulant Treatment for Prevention of Venous Thromboembolism (VTE) in Patients With Acute Primary Intracerebral Hemorrhage (ICH)	Unknown status	NCT00699465	Phase 4	enoxaparin;enoxaparin placebo
6	The Danish Non-vitamin K Antagonist Oral Anticoagulation Study. A Cluster Randomized Study Comparing Safety and Efficacy of Edoxaban, Apixaban, Rivaroxaban and Dabigatran for Oral Anticoagulation in Patients With Venous Thromboembolism.	Unknown status	NCT03129555	Phase 4	Dabigatran Etexilate Oral Capsule;Rivaroxaban Oral Tablet;Edoxaban Oral Tablet;Apixaban Oral Tablet
7	A Randomized Study Aimed at Comparing Activated Partial Thromboplastin Time and Anti-Xa Activity and in Patients Requiring Unfractionated Heparin Infusion	Unknown status	NCT03426982	Phase 4	Unfractionated heparin
8	Outcome of Percutaneous Mechanical Thrombectomy to Treat Acute Deep Venous Thrombosis	Unknown status	NCT02959801	Phase 4
9	The Efficacy and Safety of Prophylactic Anticoagulation for Catheter-related Thrombosis in Patients With Cancer and Implantable Venous Access Ports: a Prospective Multi-center Randomized Controlled Trial.	Unknown status	NCT04256525	Phase 4	Rivaroxaban 10mg;Aspirin 100mg;low molecule heparin
10	Comparison of Ultra-low-dose Oral Versus Trans-dermal Hormone Therapy on Coagulation Activation and Metabolic Risk Factors for Cardiovascular Disease	Unknown status	NCT02264743	Phase 4	Femoston Conti;EVOREL® CONTI
11	Two Weeks of Low Molecular Weight Heparin for Distal Vein Thrombosis (TWISTER)	Unknown status	NCT01252420	Phase 4	Enoxaparin
12	Efficacy and Safety of Warfarin Anticoagulation for Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy	Unknown status	NCT02238444	Phase 4	Warfarin;Dipyridamole;Aspirin;Low Molecular Weight Heparin
13	Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis：A Zelen-design Multicenter Randomized Controlled Trial	Unknown status	NCT02630095	Phase 4	Nadroparin Calcium and Warfarin
14	Residual Vein Thrombosis Establishes the Optimal Duration of Low Molecular Weight Heparins in Cancer Patients With Deep Vein Thrombosis of the Lower Limbs	Unknown status	NCT00450645	Phase 4	low molecular weight heparin
15	Study of the OmniWave Endovascular System in Subjects With Lower and Upper Extremity Deep Vein Thrombosis - SONIC I Study	Unknown status	NCT00640731	Phase 4
16	Dose Effect of Tranexamic Acid on the Incidence of Deep Venous Thrombus in Cardiac Surgery With Cardiopulmonary Bypass	Unknown status	NCT03838328	Phase 4	Tranexamic Acid
17	Reload of High Dose Atorvastatin for Preventing Deep Vein Thrombosis in Statin Users Undergoing Total Knee Replacement Arthroplasty: RE-STOP-DVT Study- A Prospective Randomized Controlled Trial	Unknown status	NCT01063426	Phase 4	High dose Atorvastatin+enoxaparin;Enoxaparin
18	A Zelen-design Randomized Controlled Trial of the Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis	Unknown status	NCT02398357	Phase 4	Nadroparin Calcium and Warfarin
19	Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients	Unknown status	NCT01610141	Phase 4
20	Rosuvastatin for Prevention of Deep Vein Thrombosis in Patients Undergoing Total Knee Replacement Arthroplasty: STOP DVT - A Prospective Randomized Controlled Trial	Unknown status	NCT01021488	Phase 4	Rosuvastatin 20mg/d for 14days;enoxaparin only
21	Comparison of Low-Molecular-Weight Heparin (LMWH) and Unfractionated Heparin (UFH) in Combination With Thrombolytic Treatment of Acute Massive Pulmonary Thromboembolism	Unknown status	NCT01956955	Phase 4	enoxaparin ,alteplase, unfractionated heparin
22	Prospective, Pharmacokinetic Study for Determination of the Relationship Between Lean Body Weight and Anti-Xa Activity 4 Hours After Subcutaneous Injection of 5700 IU Nadroparin in Morbidly Obese Patients After Bariatric Surgery.	Unknown status	NCT02295150	Phase 4	Nadroparin
23	Thromboprophylaxis During Bariatric Surgery	Unknown status	NCT00444652	Phase 4	Enoxaparin
24	Low Dose Rt-PA Plus LMWH Compared With LMWH Alone for the Treatment of Normotensive Pulmonary Embolism Patients With Acute RV Dysfunction: A Randomized，Multi-Center，Controlled Trial	Unknown status	NCT01531829	Phase 4	Recombinant tissue plasminogen activator (rt-PA);Low Molecular Weight Heparin
25	Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy	Completed	NCT04352439	Phase 4	Aspirin
26	Prospective, Multicenter Study Investigating Efficacy and Safety of Oral Rivaroxaban for the Prevention of Recurrent Venous Thromboembolism in Korean Patients With Cancers	Completed	NCT01989845	Phase 4	Rivaroxaban
27	Effectiveness of Weight-adjusted Prophylactic Low Molecular Weight Heparin Doses Compared With Lower Fixed Prophylactic Doses to Prevent Venous Thromboembolism in COVID-2019. The Multicenter Randomized Controlled Open-label Trial COVI-DOSE	Completed	NCT04373707	Phase 4	Enoxaparin
28	Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism: The Pilot Study	Completed	NCT02559856	Phase 4	Apixaban;Rivaroxaban
29	Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy	Completed	NCT02958969	Phase 4	Apixaban
30	Randomized Clinical Trial of Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients Undergoing Chemotherapy Treatment.	Completed	NCT00966277	Phase 4	Dalteparin
31	Evaluation of Venous Thromboembolism Prevention in High-Risk Trauma Patients: A Prospective Randomized Trial of Standard Enoxaparin Versus Two Anti-Xa Adjusted Dosing Strategies	Completed	NCT02412982	Phase 4	Enoxaparin 40 mg q12h;Enoxaparin 30 mg q8h
32	An Open-Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin in the Prevention of Venous Thromboembolism in Patients Following Acute Ischemic Stroke	Completed	NCT00077805	Phase 4	Enoxaparin sodium
33	FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism	Completed	NCT00942968	Phase 4	dalteparin
34	Venous Thromboembolism Prevention in the Morbidly Obese Medically Ill Patient: A Pharmacological Analysis of the Predictability of Prophylactic Weight-Based Enoxaparin Dosing.	Completed	NCT00585182	Phase 4	Enoxaparin 0.5 mg/kg once daily
35	Clinically-Important Venous Thromboembolism Following Lower Extremity Fractures: Epidemiology & Prevention	Completed	NCT00187408	Phase 4	Low Molecular Weight Heparin (dalteparin)
36	REVERSEII: Validation of the "Men and HERDOO2"- A Clinical Decision Rule to Identify Patients With "Unprovoked" Venous Thromboembolism Who Can Discontinue Anticoagulants After 6 Months of Treatment.	Completed	NCT00967304	Phase 4
37	Towards Improved Adherence With Extended Venous Thromboembolism Prophylaxis After Abdominal or Pelvic Major Cancer Surgery	Completed	NCT04479579	Phase 4	Apixaban 2.5 milligram
38	Safety of Fondaparinux as Postpartum Venous Thromboembolism Prophylaxis	Completed	NCT04447378	Phase 4	Fondaparinux 2.5Mg/0.5Ml Inj Syr
39	D-dimer Test to Establish Duration of Anticoagulation After a First Idiopathic Episode of Venous Thromboembolism; the Prospective Randomized "Prolong" Study	Completed	NCT00264277	Phase 4	Vitamin K antagonist (Coumarin anticoagulants)
40	Evaluation of Non-Surgical Venous Thromboembolism Prophylaxis Dosing Strategies: Enoxaparin 20mg Versus 30mg Subcutaneously Once Daily in Elderly Patients With Impaired Renal Function	Completed	NCT03158792	Phase 4	Enoxaparin 20Mg/0.2mL Prefilled Syringe;Enoxaparin 60Mg/0.6Ml Inj Syringe 0.6Ml
41	Weight-Adjusted Dosing of Tinzaparin in Pregnancy	Completed	NCT00851864	Phase 4	Tinzaparin
42	Impact of Rabeprazole-induced Elevated Gastric pH on APO-Dabigatran Exposure in Healthy Volunteers	Completed	NCT04157881	Phase 4	RABEprazole 20 Mg Oral Delayed Release Tablet;APO-Dabigatran 150mg
43	Phase IV, Randomized, Open-Label Trial Comparing Long-Term Subcutaneous Low-Molecular Weight Heparin With Oral Anticoagulant Therapy in the Treatment of Deep Venous Thrombosis	Completed	NCT00689520	Phase 4	tinzaparin;acenocoumarol
44	Plasma Anti-FXa Concentration After Continuous Intravenous Infusion and Subcutaneous Dosing of Enoxaparin for Thromboprophylaxis in Critically Ill Patients	Completed	NCT02095509	Phase 4	Enoxaparin
45	EUropean Pharmacogenetics of AntiCoagulant Therapy - Phenprocoumon	Completed	NCT01119274	Phase 4
46	EUropean Pharmacogenetics of AntiCoagulant Therapy - Acenocoumarol	Completed	NCT01119261	Phase 4
47	Use of TRanEXamic Acid in Reduction Mammoplasty (TREX-ARM): a Double-blinded Randomized Controlled Trial	Completed	NCT04947514	Phase 4	Tranexamic acid
48	A Multicenter, Randomized-Controlled Trial to Evaluate the Efficacy and Safety of Antithrombotic Therapy for Prevention of Arterial and Venous Thrombotic Complications in Critically-Ill COVID-19 Patients	Completed	NCT04409834	Phase 4	Unfractionated Heparin IV;Enoxaparin 1 mg/kg;Clopidogrel;Unfractionated heparin SC;Enoxaparin 40 Mg/0.4 mL Injectable Solution
49	EUropean Pharmacogenetics of AntiCoagulant Therapy - Warfarin	Completed	NCT01119300	Phase 4
50	A Non-Randomized Prospective Study of IVC Filter Retrieval	Completed	NCT00196118	Phase 4

Search NIH Clinical Center for Thrombophilia Due to Thrombin Defect

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

anisindione

apixaban

ardeparin

ardeparin sodium

argatroban

Dalteparin

Dalteparin Sodium

danaparoid

Danaparoid sodium

Dicumarol

Enoxaparin

fondaparinux

heparin

heparin calcium

heparin sodium

HEPARIN SODIUM (BEEF LUNG)

heparin sodium, bovine

heparin sodium, porcine

lepirudin

Papaverine

Papaverine Hydrochloride

Phenprocoumon

rivaroxaban

Streptokinase

tinzaparin

Tinzaparin sodium

Urokinase

Warfarin

Warfarin Sodium

WARFARIN SODIUM ISOPROPANOL COMPLEX

Sources

Genetic Tests for Thrombophilia Due to Thrombin Defect

Genetic tests related to Thrombophilia Due to Thrombin Defect:

#	Genetic test	Affiliating Genes
1	Thrombophilia Due to Thrombin Defect ²⁸	F13A1 F2 HABP2 MTHFR
2	Venous Thrombosis ²⁸
3	Venous Thrombosis, Susceptibility to ²⁸
4	Venous Thromboembolism, Susceptibility to ²⁸
5	Thromboembolism, Susceptibility to ²⁸

Sources

Anatomical Context for Thrombophilia Due to Thrombin Defect

Organs/tissues related to Thrombophilia Due to Thrombin Defect:

MalaCards : Lung, Spinal Cord, Liver, Heart, Brain, Breast, Endothelial

ODiseA: Blood And Bone Marrow

Sources

Publications for Thrombophilia Due to Thrombin Defect

Articles related to Thrombophilia Due to Thrombin Defect:

(show top 50) (show all 50975)

#	Title	Authors	PMID	Year
1	The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. ⁵³ ⁶² ⁵⁷ ⁵	De Stefano V...Leone G	10477778	1999
2	A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. ⁵³ ⁶² ⁵⁷ ⁵	Poort SR...Bertina RM	8916933	1996
3	Frequent factor II G20210A mutation in idiopathic portal vein thrombosis. ⁶² ⁵⁷ ⁵	Chamouard P...Oudet P	9869612	1999
4	Thrombosis from a prothrombin mutation conveying antithrombin resistance. ⁵⁷ ⁵	Miyawaki Y...Kojima T	22716977	2012
5	Clinical and analytical relevance of the combination of prothrombin 20210A/A and factor V Leiden: results from a large family. ⁵⁷ ⁵	Corral J...Vicente V	10233438	1999
6	Marburg I polymorphism of factor VII-activating protease is associated with idiopathic venous thromboembolism. ⁵³ ⁶² ⁵	Hoppe B...Salama A	15486068	2005
7	Prevalence and Geographical Variation of Prothrombin G20210A Mutation in Patients with Cerebral Vein Thrombosis: A Systematic Review and Meta-Analysis. ⁶² ⁵	Gonzalez JV...Gandara E	27031503	2016
8	Management of inherited thrombophilia: guide for genetics professionals. ⁶² ⁵⁷	Varga EA...Kujovich JL	21707594	2012
9	A follow-up study of a genome-wide association scan identifies a susceptibility locus for venous thrombosis on chromosome 6p24.1. ⁶² ⁵⁷	Morange PE...Rosendaal FR	20226436	2010
10	The genetics of venous thromboembolism. A meta-analysis involving approximately 120,000 cases and 180,000 controls. ⁶² ⁵	Gohil R...Sharma P	19652888	2009
11	Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. ⁶² ⁵	Segal JB...Bass EB	19531787	2009
12	Functional polymorphisms of FGA, encoding alpha fibrinogen, are associated with susceptibility to venous thromboembolism in a Taiwanese population. ⁶² ⁵	Ko YL...Lee YS	16362348	2006
13	A novel polymorphism in the factor XIII B-subunit (His95Arg): relationship to subunit dissociation and venous thrombosis. ⁶² ⁵	Komanasin N...Ariens RA	16241947	2005
14	Genetic susceptibility to venous thrombosis. ⁶² ⁵⁷	Seligsohn U...Lubetsky A	11309638	2001
15	alpha-fibrinogen Thr312Ala polymorphism and venous thromboembolism. ⁶² ⁵	Carter AM...Grant PJ	10910940	2000
16	Homozygotes for prothrombin gene 20210 A allele in a thrombophilic family without clinical manifestations of venous thromboembolism. ⁶² ⁵	Souto JC...Fontcuberta J	10406905	1999
17	Factor XIII Val34Leu is a genetic factor involved in the etiology of venous thrombosis. ⁶² ⁵	Franco RF...Zago MA	10365735	1999
18	Born to clot: the European burden. ⁶² ⁵	Rees DC...Clegg JB	10233439	1999
19	Venous thrombosis as a chronic disease. ⁶² ⁵⁷	Schafer AI	10089190	1999
20	A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. ⁶² ⁵⁷	Kearon C...Julian JA	10089183	1999
21	A single genetic origin for the common prothrombotic G20210A polymorphism in the prothrombin gene. ⁶² ⁵	Zivelin A...Seligsohn U	9694698	1998
22	Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. ⁶² ⁵	Doggen CJ...Rosendaal FR	9531249	1998
23	GoldVariants, a resource for sharing rare genetic variants detected in bleeding, thrombotic, and platelet disorders: Communication from the ISTH SSC Subcommittee on Genomics in Thrombosis and Hemostasis. ⁵	Megy K...Freson K	34355501	2021
24	A Novel Heterozygous Variant in F2 Gene in a Chinese Patient With Coronary Thrombosis and Acute Myocardial Infarction Leads to Antithrombin Resistance. ⁵	Tang Y...Fan LL	32194638	2020
25	Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders. ⁵	Downes K...Freson K	31064749	2019
26	HABP2 Mutation and Nonmedullary Thyroid Cancer. ⁵	Zhao X...Zhang X	26581002	2015
27	HABP2 Mutation and Nonmedullary Thyroid Cancer. ⁵	Zhou EY...Yang Y	26581003	2015
28	HABP2 Mutation and Nonmedullary Thyroid Cancer. ⁵	Tomsic J...de la Chapelle A	26581005	2015
29	HABP2 Mutation and Nonmedullary Thyroid Cancer. ⁵	Sponziello M...Filetti S	26581004	2015
30	HABP2 Mutation and Nonmedullary Thyroid Cancer. ⁵	Gara SK...Kebebew E	26581001	2015
31	Germline HABP2 Mutation Causing Familial Nonmedullary Thyroid Cancer. ⁵	Gara SK...Kebebew E	26222560	2015
32	A mutation in the HFE gene is associated with altered brain iron profiles and increased oxidative stress in mice. ⁵	Nandar W...Connor JR	23429074	2013
33	Effect of HFE variants on sphingolipid expression by SH-SY5Y human neuroblastoma cells. ⁵	Ali-Rahmani F...Schengrund CL	21243428	2011
34	HFE polymorphisms affect cellular glutamate regulation. ⁵	Mitchell RM...Connor JR	19560233	2011
35	Mutant HFE H63D protein is associated with prolonged endoplasmic reticulum stress and increased neuronal vulnerability. ⁵	Liu Y...Connor JR	21349849	2011
36	Genetic screening for HFE hemochromatosis in 6,020 Danish men: penetrance of C282Y, H63D, and S65C variants. ⁵	Pedersen P...Milman N	19159930	2009
37	HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis-related morbidity. ⁵	Gurrin LC...HealthIron Study Investigators	19554541	2009
38	Factor XIII Val34Leu variant and the risk of myocardial infarction: a meta-analysis. ⁵	Shafey M...Wells PS	17393027	2007
39	Prothrombin 20210G>A is an ancestral prothrombotic mutation that occurred in whites approximately 24,000 years ago. ⁵	Zivelin A...Seligsohn U	16493002	2006
40	Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls. ⁵	Casas JP...Sharma P	15534175	2004
41	The prothrombin 3'end formation signal reveals a unique architecture that is sensitive to thrombophilic gain-of-function mutations. ⁵	Danckwardt S...Kulozik AE	15059842	2004
42	Genetic variants of coagulation factor XIII, postmenopausal estrogen therapy, and risk of nonfatal myocardial infarction. ⁵	Reiner AP...Psaty BM	12456499	2003
43	Marburg I polymorphism of factor VII--activating protease: a prominent risk predictor of carotid stenosis. ⁵	Willeit J...Roemisch J	12578864	2003
44	The frequent Marburg I polymorphism impairs the pro-urokinase activating potency of the factor VII activating protease (FSAP). ⁵	Roemisch J...Weimer T	12138371	2002
45	The effect of the Val34Leu polymorphism in the factor XIII gene in infants with a birth weight below 1500 g. ⁵	Gopel W...Genetic Factors in Neonatology Study Group	12072871	2002
46	Co-selection of the H63D mutation and the HLA-A29 allele: a new paradigm of linkage disequilibrium? ⁵	Cardoso CS...Porto G	11904676	2002
47	A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation. ⁵	Gochee PA...Olynyk JK	11874997	2002
48	Unilateral chronic thromboembolic pulmonary disease associated with combined inherited thrombophilia. ⁵	Laczika K...Kyrle PA	11796466	2002
49	[A family with multiple thrombosis including infancy occurrence]. ⁵⁷	Sakai M...Shirahata A	11570053	2001
50	Thrombophilic gene mutations and recurrent spontaneous abortion: prothrombin mutation increases the risk in the first trimester. ⁵	Pihusch R...Thaler CJ	11506076	2001

Sources

Genes for Thrombophilia Due to Thrombin Defect

Genes related to Thrombophilia Due to Thrombin Defect (5 elite genes):

(show all 25)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	F13A1	Coagulation Factor XIII A Chain	Protein Coding	1079.93	Molecular basis known ⁵⁷ Pathogenic ⁵ Genetic Tests ²⁸ Susceptibility factor ⁵⁷ Protective ⁵ DISEASES inferred ¹⁴	8025280 9459313 9550516 (more) 10365735 10910914 12072871 12456499 17393027
2	F2	Coagulation Factor II, Thrombin	Protein Coding	1058.14	Molecular basis known ⁵⁷ Pathogenic ⁵ Genetic Tests ²⁸ Risk factor ⁵ DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders (show sections)	2222810 2429850 6305407 (more) 8696333 8896550 8916933 9106528 9292507 9462220 9493607 9531249 9569177 9694698 9869612 10027711 10233438 10233439 10336270 10348710 10348711 10348712 10406905 10477778 10544935 11358905 11443298 11506076 11796466 11874997 11904676 15534175 16493002 19159930 19531787 19554541 19560233 21243428 21349849 22716977 23429074 34355501 15059842 19652888 27031503 32194638 12871547 11734673 11836169 14531916 9792287 10189382 12195688 10073976 15628909 16261289 11167765 15692250 9299966 9211625 19524925 16082606 10828960 9548316 7580067 16610253 15637132 10323091 9861761 1581150 15692238 11684865 11153741 10456623 10235429 9605787 18403391 11518821 11380448 10666427 7496550 19414836 18983490 14669613 10963782 9423788 1939315 8135917 17401546 12751694 11071624 10759281 10669145 11434083 9380637 15711747 15353918 12871361 10779421 10974337 8339409 17059428 9364981 10912662 7740515 12730085 11555702 11084577 9238178 9308741 9851733 10655256 12911579 16189654 1642580 10894919 16823828 17145624 14652637 12879433 12787541 12709363 11854725 11375285 10904101 17334933 17440049 17461930 16880142 11951068 11583311 11122096 12490067 11860303 11369682 9714136 9531030 9423789 17890946 17156138 16627257 15989814 12471642 11583310 10856982 9198137 8165610 8260336 17597608 19412729 18257465 11718704 11193048 10650849 10650846 7892570 10726011 19353312 16466010 10669148 11292189 12506014 12847589
3	HABP2	Hyaluronan Binding Protein 2	Protein Coding	686.89	Molecular basis known ⁵⁷ Genetic Tests ²⁸ Susceptibility factor ⁵⁷ Risk factor ⁵ DISEASES inferred ¹⁴ Novoseek inferred ⁵³	26222560 26581003 26581004 (more) 26581005 26581001 26581002 12138371 12578864 15486068 16543963 18278202 16676090 16461761 17479202 16676091 18605956
4	MTHFR	Methylenetetrahydrofolate Reductase	Protein Coding	672.73	Molecular basis known ⁵⁷ Genetic Tests ²⁸ Susceptibility factor ⁵⁷ DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17550314 12384649 20429317 (more) 10974337 12605391 18498357 1998339 11943942 12570104 15353918 15711747 15355664 12214149 14624217 15226189 15886665 11011848 16082606 12165282 12439143 15847749 15458711 17452895 14669613 10505325 10091425 20229089 10235429 9490685 10837091 18293456 17353498 10192659 18800176 10477457 10655256 16881367 16607075 18030499 10650848 12709363 11122096 11084577 10759281 9869151 9515147 12428084 11592438 9775112 12803132 12490067 11096270 9733454 17156138 15096570 10360908 9459321 18941937 18333369 17442092 12747593 9440395 20064497 10233437 19131586 17591934 16320157 15989003 11018168 9609218 15670035 17360059 17160942 18318759 19353312
5	PLOD1	Procollagen-Lysine,2-Oxoglutarate 5-Dioxygenase 1	Protein Coding	400	Pathogenic ⁵
6	FGA	Fibrinogen Alpha Chain	Protein Coding	40.62	Risk factor ⁵ DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10910940 16362348 8222189 (more) 8426084
7	PROC	Protein C, Inactivator Of Coagulation Factors Va And VIIIa	Protein Coding	39.85	Likely pathogenic ⁵ Novoseek inferred ⁵³	31064749 11434940 8462980 (more) 11264150 9788727 1511989 8499568 7881411 7605880 7548679 1511988
8	F5	Coagulation Factor V	Protein Coding	27.26	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9092318 12468175 10215560 (more) 11734673 14996674 11165549 9382368 9424976 11529695 11167765 15638861 11920167 12749008 10943572 10102457 12368162 18217158 10764192 20177282 8917233 9792287 9822524 10189382 16579319 11583312 11305729 10726047 10070834 19592474 15711747 11877263 11471205 10556190 8616099 16882132 16026277 9698021 7586244 18796457 17605877 14531916 12960604 9269773 15855479 11737249 10349814 10195932 10063991 9858248 9010145 17650440 10361512 11958494 11153741 10086652 9263726 9107163 17139368 10368524 10695766 15670037 10666427 17499343 16807645 7908377 8083377 9836075 10545058 10643310 10414227 12871361 12464993 12195688 11816705 11726323 11167771 10974337 10870810 10744162 11406725 11372668 10930988 10235434 10073976 10075628 10667107 10582976 9666536 17525392 17068406 16361766 16446869 16575256 16241958 15353918 14996015 14966073 11091190 10828239 9471929 10477778 16758522 17200768 12434659 15820946 11725376 9949170 8705909 16601846 9923779 20368522 9046944 16532157 11715503 12877675 10928623 9753484 10192659 8902988 12428084 11734663 8616046 16518527 8979136 7968118 9375883 9454742 10807758 15618258 14616826 11342806 10051291 9168376 9125617 9109469 7493138 18980946 15583739 11084577 10756364 10756665 10612220 9198201 8644593 9858251 9184387 16765424 16137798 14534468 11529632 10449697 9746774 8302317 7877648 18248600 15815078 12544728 11460958 11114134 9895336 9763354 9659505 9423813 8966815 17890946 15745078 14752712 19707484 12270010 10807757 10192660 8943855 8624369 20218141 11037865 10726048 11583310 11374681 10678587 10169621 9173065 16607075 15033664 7815875 7899365 7608792 9637902 10544904 10994152 10767687 10706899 10669148 10655256 10507841 10448635
9	SERPINC1	Serpin Family C Member 1	Protein Coding	26.47	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1696577 12542252 9479609 (more) 12492585 15140129 1450321 10449697 7959685 2012760 7627635 11755949 10521389 11951068 8257185 8327986 1505975 8217045 11396643 8186357 8469479 8317013 2106195 9736420 11685049 12616091 9746774 9396341 9411284 9171870 8733245 2146406 20078811 18393143 15170430 1758145 1747261 19277409 17244682 15989003 12894373 7831651 8291376 1906811 7482430 8165635 8334580 1390220 1533414 2320274 19139080 17610610 17461930 15809328 11725376 11075405 10534704 9462558 9107094 8519788 8584990 12471642 11694407 11301618 10856982 9818998 9198244 9184384 8545427 11302483 11798535 10912662 9290713 9266933 7703480 1725646 1796409 1674436 2017691 2325220 16614732 15710578 12695749 10650846 8235184 1571206 8418545 18394759 15924156 12787541 11472362 10456616 10230891 10634159 12601491 10227770 9488784 1489375 19932950 8743182 19132194 19514602 10515862 11127851 9342999 11506257 10195932 15978097 17443678 16330983 8562839 18824642 2339350 15370205 9922933 10572082 17555454 7965163 7839322 8967705 16676077 1287876 8839395 10556190 7888369 1579895 2237157 15711747 14728051 11672578 10969675 10667107 19177736 17433903 16575261 16240880 15259286 12916552 11190907 10669145 16305519 17370730 12675726 10073951 10705622 9372103 1536145 1836241 1868237 12239149 19837548 19214913 18772359 17626316 10666427 8091378 11895779 11204840 9423788 8624369 1553002 1836072 1973278 10987006 10063991 10358455 9108706 8831253 7937056 1643210 16512831 8815842 7944258 8273075 2098299 16244492 17006373 15233593 14624217 12385861 12368166 12172465 11721729 11522012 8685111 9827940 9157603 7817365 20047788 9850619 10468144 10974337
10	F13B	Coagulation Factor XIII B Chain	Protein Coding	25	Risk factor ⁵	16241947 12456499
11	F3	Coagulation Factor III, Tissue Factor	Protein Coding	18.88	Novoseek inferred ⁵³	1658403 10678587 19095643 (more) 9522600 10456444 12871353 15140126 8778420 10712418 11843891 10769107 17181160 9716167 8156489 9596667 8694666 1802471 16527335 16880142 9100165 9067499 11408746 8470049 8557786 7482401 10510988 18328308 17504985 10631865 16093806 9531224 17940484 16846482 19888523 11156884 16937466 7947259 8179457 16634742 10331096 8135917 12844328 10444187 9385299 9299966 16706989 15297315 9767923 8616099 8267489 8917233 11306905 7887755 15034796 2166971
12	APOH	Apolipoprotein H	Protein Coding	18.78	Novoseek inferred ⁵³	9576405 12472581 16444460 (more) 12685247 8485565 14728051 1509416 12787540 16451395 9031482 9578894 14617012 7795618 7933603 9603414 8508712 17644740 15628909 1443986 16409447 7781279 8170264 9541098 20069154 1907589 11697705 2385560 7883863 9167020 11787868 12428085 11202118 12601491 7699232 18438797 15987300 15094665 12589595 9875649 18666184 19028366 15345914 15378261 14621047 12393574 12020188 9054646 8638627 8016420 19090981 10389322 20200695 17916984 16131440 14974901 11873090 10942975 9626773 9187233 7618434 18714484 11331837 11126275 9270531 15968383 7849429 8371501 1301991 19455050 15498444 12695749 12595612 7792418 11305488 15794193 17354591 18159581 2376955 2291381 1825446
13	F10	Coagulation Factor X	Protein Coding	18.41	Novoseek inferred ⁵³	11434677 9241747 9336303 (more) 10813384 19412729 15781750 8786532 16338245 12871371 12565931 15748242 18579812 12643903 12244487 16409461 19485937 16241946 14650860 12172443 12695266 15316429 16156684 19132191 17627564 16547433 2166377 20424539 17893411 17076521 14983229 12820819 12501872 19561526 17292948 16758650 16758648 15317403 14726838 19719335 17549294 16175516 15744699 12597061 11549781 20178047 17874721 17323591 15304033 14704589 14650863 15341703 15233593 19407299 19644596 1847026 16146728 16253651 16305517
14	F8	Coagulation Factor VIII	Protein Coding	15.87	Novoseek inferred ⁵³	14635611 15662616 16732372 (more) 12353065 11214218 19029445 15353485 16513639 17393014 15735794 12472583 17189302 13677265 19105508 17155964 15606555 12871371 12871460 16482798 1796409 9798969 11886466 12439142 14598591 16052298 11156867 18000609 11736955 15634269 15467909 18304616 17074720 15692250 12871536 15735796 15213843 18449420 14984502 9184386 17938765 15849522 15304037 14675089 12719781 16684011 16175004 18704643 18931845 12567199 10669146 15798145 14510956 16977571 17524760
15	VWF	Von Willebrand Factor	Protein Coding	15.56	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9459348 7703064 17393014 (more) 7823669 9490916 15735532 16568319 1796409 15606555 15662616 19105508 11487001 17364690 17189302 20096009 11156867 20008188 12439142 16888271 9184386 10695766 11288984 16490435 19760588
16	SERPINE1	Serpin Family E Member 1	Protein Coding	15.29	Novoseek inferred ⁵³	9609232 12421149 9569196 (more) 8478593 1455392 8792730 12439142 17059414 19214913 10930990 18160588 17549286 14652637 16052298 11457466 11091191 20017074 1572039 10807758 17850750 8743732 9372104 10073956 15668194 12682447 8379599 8518417 20056540 19739037 8739849 8994417 17206678 8052957 10650849
17	PLAT	Plasminogen Activator, Tissue Type	Protein Coding	15.09	Novoseek inferred ⁵³	19592415 1853306 12000444 (more) 16167916 1455392 12439142 11457466 15976969 11552059 17059414 11137937 1572039 1330023 9053819 9536645 16466010 2106783 11854725 19566947 14983192 7820108 1309056 1641820 1909902 2129142 1694738 16369579 15064337 14752684 12643326 8322122 1412204 12845330 1394932 11265890 1906351 1342779 11246666 18004620 9112141
18	THBD	Thrombomodulin	Protein Coding	14.76	Novoseek inferred ⁵³	1658403 11231927 11408746 (more) 8073391 10856982 13679649 16353054 11986219 12139752 16026278 2156578 15842356 17080211 12439142 1333021 12211414 2170704 10195941 15869592 9020374 16490435 18485081
19	PF4	Platelet Factor 4	Protein Coding	14.58	Novoseek inferred ⁵³	16342191 11827497 11442479 (more) 19521017
20	PROCR	Protein C Receptor	Protein Coding	14.38	Novoseek inferred ⁵³	16113830 15921724 19222470 (more) 18278202 18757851 12439143 11776299 15304035 17570903 12152660 13679649 18403391 18515879
21	TNXA	Tenascin XA (Pseudogene)	Pseudogene	13.9	Novoseek inferred ⁵³	7919374 2166971 9768037 (more) 15585445 12820819
22	CBS	Cystathionine Beta-Synthase	Protein Coding	12.44	Novoseek inferred ⁵³	9490685 17160942 9712328 (more) 9864922 20174770 10807759 10235428 12227460 12439143 10564686 14518832
23	HRG	Histidine Rich Glycoprotein	Protein Coding	11.93	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8478593 10650849
24	SELP	Selectin P	Protein Coding	11.76	Novoseek inferred ⁵³	10651744 14983399 15947544 (more) 11916065 11916067 16411411 17549288 18449419 15217633 17510305 16293978 17550854 18539899
25	F9	Coagulation Factor IX	Protein Coding	11.58	Novoseek inferred ⁵³	19617576 12406910 12172465 (more) 15692250 16610253 12871536 18194306 18409149 10845896 11434677 17073609 9198137 12871460 12871371

Sources

Variations for Thrombophilia Due to Thrombin Defect

ClinVar genetic disease variations for Thrombophilia Due to Thrombin Defect:

⁵ (show top 50) (show all 266)

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	F13A1	NM_000129.4(F13A1):c.103G>T (p.Val35Leu)	SNV	Protective	16532	rs5985	GRCh37: 6:6318795-6318795 GRCh38: 6:6318562-6318562
2	F2	NM_000506.5(F2):c.1787G>T (p.Arg596Leu)	SNV	Pathogenic	31922	rs387907201	GRCh37: 11:46760876-46760876 GRCh38: 11:46739326-46739326
3	PLOD1	GRCh37/hg19 1p36.22(chr1:12019879-12028775)	CN GAIN	Pathogenic	523241		GRCh37: 1:12019879-12028775 GRCh38:
4	F13A1	NM_000129.4(F13A1):c.1184C>T (p.Ala395Val)	SNV	Pathogenic	911739	rs76451285	GRCh37: 6:6197488-6197488 GRCh38: 6:6197255-6197255
5	F2	NM_000506.5(F2):c.*97G>A	SNV	Pathogenic Risk Factor	13310	rs1799963	GRCh37: 11:46761055-46761055 GRCh38: 11:46739505-46739505
6	F2	NM_000506.5(F2):c.1787G>A (p.Arg596Gln)	SNV	Pathogenic	692073	rs387907201	GRCh37: 11:46760876-46760876 GRCh38: 11:46739326-46739326
7	PROC	NM_000312.4(PROC):c.238-2A>G	SNV	Likely Pathogenic	627040	rs1573442055	GRCh37: 2:128180491-128180491 GRCh38: 2:127422915-127422915
8	HABP2	NM_004132.5(HABP2):c.1601G>A (p.Gly534Glu)	SNV	Risk Factor	5974	rs7080536	GRCh37: 10:115348046-115348046 GRCh38: 10:113588287-113588287
9	FGA	NM_021871.4(FGA):c.991A>G (p.Thr331Ala)	SNV	Risk Factor	16420	rs6050	GRCh37: 4:155507590-155507590 GRCh38: 4:154586438-154586438
10	PROC	NM_000312.4(PROC):c.352T>C (p.Phe118Leu)	SNV	Likely Pathogenic	469122	rs1553424043	GRCh37: 2:128180699-128180699 GRCh38: 2:127423123-127423123
11	F13B	NM_001994.3(F13B):c.344G>A (p.Arg115His)	SNV	Risk Factor	16520	rs6003	GRCh37: 1:197031021-197031021 GRCh38: 1:197061891-197061891
12	PROC	NM_000312.4(PROC):c.814C>T (p.Arg272Cys)	SNV	Likely Pathogenic	671	rs121918154	GRCh37: 2:128185950-128185950 GRCh38: 2:127428374-127428374
13	PROC	NM_000312.4(PROC):c.125G>A (p.Arg42His)	SNV	Likely Pathogenic	161333	rs369504169	GRCh37: 2:128178913-128178913 GRCh38: 2:127421337-127421337
14	F2	NM_000506.5(F2):c.1621C>T (p.Arg541Trp)	SNV	Likely Pathogenic	986165	rs886048338	GRCh37: 11:46751078-46751078 GRCh38: 11:46729528-46729528
15	F5	NM_000130.5(F5):c.1106C>T (p.Ala369Val)	SNV	Uncertain Significance	293631	rs200934105	GRCh37: 1:169524432-169524432 GRCh38: 1:169555194-169555194
16	F2	NM_000506.5(F2):c.813C>T (p.Gly271=)	SNV	Uncertain Significance	304811	rs5899	GRCh37: 11:46747662-46747662 GRCh38: 11:46726112-46726112
17	F5	NM_000130.5(F5):c.4309A>T (p.Thr1437Ser)	SNV	Uncertain Significance	293598	rs115148599	GRCh37: 1:169510019-169510019 GRCh38: 1:169540781-169540781
18	F2	NM_000506.5(F2):c.798C>T (p.Asp266=)	SNV	Uncertain Significance	304810	rs138260543	GRCh37: 11:46747647-46747647 GRCh38: 11:46726097-46726097
19	F5	NM_000130.5(F5):c.6589A>G (p.Ile2197Val)	SNV	Uncertain Significance	293572	rs372005449	GRCh37: 1:169483637-169483637 GRCh38: 1:169514399-169514399
20	F2	NM_000506.5(F2):c.1541A>G (p.Asn514Ser)	SNV	Uncertain Significance	304818	rs144011338	GRCh37: 11:46750998-46750998 GRCh38: 11:46729448-46729448
21	F5	NM_000130.5(F5):c.4333A>G (p.Thr1445Ala)	SNV	Uncertain Significance	293597	rs200204656	GRCh37: 1:169509995-169509995 GRCh38: 1:169540757-169540757
22	F5	NM_000130.5(F5):c.5490G>A (p.Leu1830=)	SNV	Uncertain Significance	293582	rs149092241	GRCh37: 1:169497262-169497262 GRCh38: 1:169528024-169528024
23	F5	NM_000130.5(F5):c.2222A>G (p.Asn741Ser)	SNV	Uncertain Significance	293621	rs144979314	GRCh37: 1:169512106-169512106 GRCh38: 1:169542868-169542868
24	F2	NM_000506.5(F2):c.1628G>T (p.Arg543Leu)	SNV	Uncertain Significance	304821	rs143064939	GRCh37: 11:46751085-46751085 GRCh38: 11:46729535-46729535
25	F5	NM_000130.5(F5):c.165T>C (p.Asn55=)	SNV	Uncertain Significance	293641	rs781434840	GRCh37: 1:169551754-169551754 GRCh38: 1:169582516-169582516
26	F2	NM_000506.5(F2):c.317-4G>A	SNV	Uncertain Significance	304807	rs375713715	GRCh37: 11:46744726-46744726 GRCh38: 11:46723176-46723176
27	F2	NM_000506.5(F2):c.1621C>A (p.Arg541=)	SNV	Uncertain Significance	304820	rs886048338	GRCh37: 11:46751078-46751078 GRCh38: 11:46729528-46729528
28	F5	NM_000130.5(F5):c.885C>T (p.Thr295=)	SNV	Uncertain Significance	293635	rs148752831	GRCh37: 1:169525951-169525951 GRCh38: 1:169556713-169556713
29	F5	NM_000130.5(F5):c.2241AGA[2] (p.Glu750del)	MICROSAT	Uncertain Significance	293620	rs575766548	GRCh37: 1:169512079-169512081 GRCh38: 1:169542841-169542843
30	F5	NM_000130.5(F5):c.1034G>A (p.Arg345Gln)	SNV	Uncertain Significance	293632	rs201078171	GRCh37: 1:169524504-169524504 GRCh38: 1:169555266-169555266
31	F5	NM_000130.5(F5):c.5788+4A>T	SNV	Uncertain Significance	293577	rs759428783	GRCh37: 1:169494071-169494071 GRCh38: 1:169524833-169524833
32	F5	NM_000130.5(F5):c.5001G>A (p.Pro1667=)	SNV	Uncertain Significance	746736	rs747456938	GRCh37: 1:169500231-169500231 GRCh38: 1:169530993-169530993
33	F5	NM_000130.5(F5):c.1033C>T (p.Arg345Trp)	SNV	Uncertain Significance	874622	rs746260106	GRCh37: 1:169524505-169524505 GRCh38: 1:169555267-169555267
34	F5	NM_000130.5(F5):c.628C>A (p.Gln210Lys)	SNV	Uncertain Significance	875606	rs144937515	GRCh37: 1:169528493-169528493 GRCh38: 1:169559255-169559255
35	F5	NM_000130.5(F5):c.5446C>T (p.Pro1816Ser)	SNV	Uncertain Significance	876694	rs141977229	GRCh37: 1:169497306-169497306 GRCh38: 1:169528068-169528068
36	F5	NM_000130.5(F5):c.911G>A (p.Gly304Glu)	SNV	Uncertain Significance	627404	rs865947251	GRCh37: 1:169525925-169525925 GRCh38: 1:169556687-169556687
37	PROC	NM_000312.4(PROC):c.386G>A (p.Arg129His)	SNV	Uncertain Significance	627207	rs746190838	GRCh37: 2:128180733-128180733 GRCh38: 2:127423157-127423157
38	F2	NM_000506.5(F2):c.1598G>A (p.Arg533Gln)	SNV	Uncertain Significance	1098524		GRCh37: 11:46751055-46751055 GRCh38: 11:46729505-46729505
39	F5	NM_000130.5(F5):c.*288T>C	SNV	Uncertain Significance	876512	rs116921763	GRCh37: 1:169483263-169483263 GRCh38: 1:169514025-169514025
40	F5	NM_000130.5(F5):c.1158A>G (p.Gln386=)	SNV	Uncertain Significance	876513	rs148623862	GRCh37: 1:169521933-169521933 GRCh38: 1:169552695-169552695
41	F5	NM_000130.5(F5):c.586+11C>A	SNV	Uncertain Significance	876600	rs199638362	GRCh37: 1:169529781-169529781 GRCh38: 1:169560543-169560543
42	F5	NM_000130.5(F5):c.5729C>T (p.Pro1910Leu)	SNV	Uncertain Significance	876651	rs200805004	GRCh37: 1:169494134-169494134 GRCh38: 1:169524896-169524896
43	F5	NM_000130.5(F5):c.4347G>A (p.Pro1449=)	SNV	Uncertain Significance	876842	rs145732153	GRCh37: 1:169509981-169509981 GRCh38: 1:169540743-169540743
44	F2	NM_000506.5(F2):c.814G>A (p.Val272Met)	SNV	Uncertain Significance	877749	rs199558597	GRCh37: 11:46747663-46747663 GRCh38: 11:46726113-46726113
45	F2	NM_000506.5(F2):c.874+13G>A	SNV	Uncertain Significance	877750	rs764029414	GRCh37: 11:46747736-46747736 GRCh38: 11:46726186-46726186
46	F2	NM_000506.5(F2):c.*9T>G	SNV	Uncertain Significance	877790	rs201577861	GRCh37: 11:46760967-46760967 GRCh38: 11:46739417-46739417
47	F2	NM_000506.5(F2):c.234G>A (p.Thr78=)	SNV	Uncertain Significance	878743	rs151121282	GRCh37: 11:46741406-46741406 GRCh38: 11:46719856-46719856
48	F2	NM_000506.5(F2):c.285G>A (p.Thr95=)	SNV	Uncertain Significance	878744	rs147892497	GRCh37: 11:46742359-46742359 GRCh38: 11:46720809-46720809
49	F2	NM_000506.5(F2):c.1298+11G>C	SNV	Uncertain Significance	879371	rs144587241	GRCh37: 11:46749724-46749724 GRCh38: 11:46728174-46728174
50	F2	NM_000506.5(F2):c.1298+19G>A	SNV	Uncertain Significance	1676733		GRCh37: 11:46749732-46749732 GRCh38: 11:46728182-46728182

Sources

Expression for Thrombophilia Due to Thrombin Defect

Search GEO for disease gene expression data for Thrombophilia Due to Thrombin Defect.

Sources

Pathways for Thrombophilia Due to Thrombin Defect

Pathways related to Thrombophilia Due to Thrombin Defect according to GeneCards Suite gene sharing:

(show all 15)

#	Super pathways	Score	Top Affiliating Genes
1	Collagen chain trimerization ⁶⁶ Show member pathways Anchoring fibril formation ⁶⁶ Assembly of collagen fibrils and other multimeric structures ⁶⁶ Blood Coagulation Cascade ⁶⁴ Collagen biosynthesis and modifying enzymes ⁶⁶ Collagen degradation ⁶⁶ Collagen formation ⁶⁶ Crosslinking of collagen fibrils ⁶⁶ Intrinsic Prothrombin Activation Pathway ⁶⁴	12.64	F10 F13A1 F13B F2 F3 F5
2	Response to elevated platelet cytosolic Ca2+ ⁶⁶ Show member pathways Disinhibition of SNARE formation ⁶⁶ Hemostasis ⁶⁶ Platelet activation, signaling and aggregation ⁶⁶ Platelet degranulation ⁶⁶	12.61	VWF THBD SERPINE1 SERPINC1 PROCR PROC
3	Complement cascade ⁶⁶ Show member pathways Activation of C3 and C5 ⁶⁶ Classical Complement Pathway ⁶⁴ Complement Pathway ⁶⁴ Complement system ⁷⁴ Complement system in neuronal development and plasticity ⁷⁴ Lectin Induced Complement Pathway ⁶⁴ Regulation of Complement cascade ⁶⁶	12.4	FGA F2 F13A1 F10
4	Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) ⁶⁶ Show member pathways Blood clotting cascade ⁷⁴ Blood Coagulation Signaling Pathways ⁶⁵ Common Pathway of Fibrin Clot Formation ⁶⁶ Complement and coagulation cascades ⁷⁴ Defective F8 binding to von Willebrand factor ⁶⁶ Defective F8 cleavage by thrombin ⁶⁶ Defective F8 sulfation at Y1699 ⁶⁶ Defective F9 activation ⁶⁶ Defective F9 secretion ⁶⁶ Defective factor IX causes hemophilia B ⁶⁶ Defective factor VIII causes hemophilia A ⁶⁶ Defective factor XII causes hereditary angioedema ⁶⁶ Defective gamma-carboxylation of F9 ⁶⁶ Diseases of hemostasis ⁶⁶ Extrinsic Pathway of Fibrin Clot Formation ⁶⁶ Extrinsic Prothrombin Activation Pathway ⁶⁴ Formation of Fibrin Clot (Clotting Cascade) ⁶⁶ Intrinsic Pathway of Fibrin Clot Formation ⁶⁶ Thrombin/protease-activated receptor (PAR) pathway ⁶¹	12.32	VWF THBD SERPINE1 SERPINC1 PROCR PROC
5	Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) ⁶⁶ Show member pathways Post-translational protein phosphorylation ⁶⁶	12.17	F2 F5 FGA PROC SERPINC1
6	Cell surface interactions at the vascular wall ⁶⁶ Show member pathways Fibronectin matrix formation ⁶⁶ PECAM1 interactions ⁶⁶ Tie2 Signaling ⁶⁶	12	THBD PROCR PROC PF4 F2
7	Gamma carboxylation, hypusine formation and arylsulfatase activation ⁶⁶ Show member pathways diphthamide biosynthesis ⁶¹ Gamma-carboxylation of protein precursors ⁶⁶ Gamma-carboxylation, transport, and amino-terminal cleavage of proteins ⁶⁶ hypusine biosynthesis ⁶¹ Hypusine synthesis from eIF5A-lysine ⁶⁶ Removal of aminoterminal propeptides from gamma-carboxylated proteins ⁶⁶ Synthesis of diphthamide-EEF2 ⁶⁶ The activation of arylsulfatases ⁶⁶ Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus ⁶⁶	11.77	PROC F8 F2 F10
8	Integrin signaling ⁶⁶ Show member pathways GRB2:SOS provides linkage to MAPK signaling for Integrins ⁶⁶ p130Cas linkage to MAPK signaling for integrins ⁶⁶ Platelet Aggregation (Plug Formation) ⁶⁶	11.69	VWF FGA F2
9	Platelet Aggregation Inhibitor Pathway, Pharmacodynamics ⁶⁰	11.38	VWF FGA F2
10	Heparin-induced Thrombocytopenia Pathway, Adverse Drug Reaction ⁶⁰	11.22	PF4 F3 F2
11	Warfarin Pathway, Pharmacodynamics ⁶⁰ Show member pathways Vitamin K metabolism and activation of dependent proteins ⁷⁴ vitamin K-epoxide cycle ⁶¹	11.15	PROC F2 F10
12	Beta2 integrin cell surface interactions ⁶¹	11.09	PROC PLAT FGA F10
13	Dissolution of Fibrin Clot ⁶⁶	10.64	SERPINE1 PLAT
14	Defective factor IX causes thrombophilia ⁶⁶ Show member pathways Defective cofactor function of FVIIIa variant ⁶⁶ Defective F8 accelerates dissociation of the A2 domain ⁶⁶ Defective F8 binding to the cell membrane ⁶⁶ Defective F8 secretion ⁶⁶ Defective F9 variant does not activate FX ⁶⁶	10.59	F8 F10
15	COVID-19, thrombosis and anticoagulation ⁷⁴	10.4	FGA F2 F13B F13A1

Sources

GO Terms for Thrombophilia Due to Thrombin Defect

Cellular components related to Thrombophilia Due to Thrombin Defect according to GeneCards Suite gene sharing:

(show all 11)

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular region	GO:0005576	10.37	APOH F10 F13A1 F13B F2 F3
2	collagen-containing extracellular matrix	GO:0062023	10.23	VWF SERPINE1 SERPINC1 PLAT PF4 FGA
3	endoplasmic reticulum lumen	GO:0005788	10.21	SERPINC1 PROC FGA F8 F5 F2
4	blood microparticle	GO:0072562	10.1	SERPINC1 FGA F2 F13A1
5	Golgi lumen	GO:0005796	10.06	PROC F8 F2 F10
6	serine-type endopeptidase complex	GO:1905370	9.92	F10 F2 PROC THBD
7	platelet alpha granule	GO:0031091	9.88	F5 FGA VWF
8	extracellular space	GO:0005615	9.88	APOH F10 F13A1 F13B F2 F3
9	platelet alpha granule lumen	GO:0031093	9.8	F13A1 F5 F8 FGA PF4 SERPINE1
10	serine protease inhibitor complex	GO:0097180	9.78	SERPINE1 PLAT
11	obsolete intrinsic component of external side of plasma membrane	GO:0031233	9.43	F3 F10

Biological processes related to Thrombophilia Due to Thrombin Defect according to GeneCards Suite gene sharing:

(show all 17)

#	Name	GO ID	Score	Top Affiliating Genes
1	proteolysis	GO:0006508	10.31	THBD PROC PLAT HABP2 F2 F10
2	blood coagulation	GO:0007596	10.09	F10 F13A1 F13B F2 F3 F5
3	platelet activation	GO:0030168	10.02	VWF PF4 FGA F2
4	positive regulation of blood coagulation	GO:0030194	9.97	APOH F2 SERPINE1
5	fibrinolysis	GO:0042730	9.97	F2 FGA PLAT SERPINE1
6	negative regulation of fibrinolysis	GO:0051918	9.96	THBD SERPINE1 PLAT F2 APOH
7	plasminogen activation	GO:0031639	9.93	PLAT FGA APOH
8	negative regulation of blood coagulation	GO:0030195	9.92	THBD SERPINE1 PROC APOH
9	blood coagulation, fibrin clot formation	GO:0072378	9.88	FGA F13B F13A1
10	negative regulation of platelet activation	GO:0010544	9.87	THBD F2
11	negative regulation of plasminogen activation	GO:0010757	9.86	SERPINE1 PLAT
12	blood coagulation, intrinsic pathway	GO:0007597	9.85	F8 APOH
13	negative regulation of coagulation	GO:0050819	9.83	PROCR PROC
14	blood coagulation, common pathway	GO:0072377	9.81	THBD FGA
15	regulation of blood coagulation	GO:0030193	9.73	SERPINC1 F2 APOH
16	regulation of body fluid levels	GO:0050878	9.55	F10 F2 F5 F8 PROC
17	hemostasis	GO:0007599	9.47	F10 F13A1 F13B F2 F3 F5

Molecular functions related to Thrombophilia Due to Thrombin Defect according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	heparin binding	GO:0008201	9.92	SERPINC1 PF4 F2 APOH
2	protease binding	GO:0002020	9.76	VWF SERPINE1 SERPINC1 F3
3	peptidase activity	GO:0008233	9.73	PROC PLAT HABP2 F2 F10
4	serine-type endopeptidase activity	GO:0004252	9.4	PROC PLAT HABP2 F3 F2 F10
5	serine-type peptidase activity	GO:0008236	9.35	PROC PLAT HABP2 F2 F10